Using M1Pram in a post-hoc analysis.
• A weight loss of 5.5kg measured at 16 weeks of treatment in people with type 1 diabetes and a body mass index greater than 30kg/m2
• Glycemic control efficacy comparable to that obtained with the commercial reference insulin Humalog® (Eli Lilly)
• These results were presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting held in Stockholm from September 19 to 23, 2022